MIRM
Mirum Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
85.00
close · 2026-10-30
value
84
cheaper than peers84
quality
25
stronger fundamentals25
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -0.2% | 83 |
| cash flow yield, latest year | 1.0% | 81 |
| earnings yield, 1 year ago | -2.2% | 79 |
| earnings yield, 2 years ago | -4.6% | 78 |
| cash flow yield, 2 years ago | -1.6% | 77 |
| earnings yield, latest year | -0.6% | 77 |
| cash flow yield, 3 years ago | -2.2% | 75 |
| earnings yield, 3 years ago | -4.7% | 72 |
| price to sales | 8.93× | 56 |
| price to book | 16.60× | 13 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -14.8% | 72 |
| revenue growth | 37.9% | 61 |
| debt to equity | 133.5% | 17 |
| return on equity | -703.0% | 2 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | $76.6M |
| employees | 369 |
| first trade | 2019-07-18 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.47 | -1.85 | -3.94 | -4.02 |
| free cash flow | $54.9M | -$10.7M | -$91.1M | -$120.4M |
| net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M |
| revenue | $521.3M | $336.9M | $186.4M | $77.1M |
| unusual items | $0 | $0 | -$49.1M | $906,000 |